Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Return on Equity (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Return on Equity for 7 consecutive years, with 0.3% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 19.0% to 0.3% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.3%, a 19.0% increase, with the full-year FY2025 number at 0.08%, up 36.0% from a year prior.
  • Return on Equity was 0.3% for Q4 2025 at Beam Therapeutics, up from 0.41% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.13% in Q1 2024 to a low of 0.91% in Q1 2021.
  • A 5-year average of 0.39% and a median of 0.41% in 2025 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: soared 201bps in 2021, then plummeted -34bps in 2024.
  • Beam Therapeutics' Return on Equity stood at 0.42% in 2021, then fell by -6bps to 0.44% in 2022, then skyrocketed by 68bps to 0.14% in 2023, then tumbled by -244bps to 0.49% in 2024, then soared by 38bps to 0.3% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Return on Equity are 0.3% (Q4 2025), 0.41% (Q3 2025), and 0.37% (Q2 2025).